The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF)

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions. To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program. “Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”